1. W. G. Hearl and M. J. Jonston, “Levels of 2′,5′-oligoadenylates in the tissues of pathogen-free mice,” in: The 2-5A System: Molecular and Clinical Aspects of the Interferon-Regulated Pathway, B. R. G. Williams and R. H. Silverman (eds.), Alan R. Liss Inc., New York, London (1985), pp. 19–24.
2. M. Esteban and E. Paez, “The 2-5A system and vaccinia virus,” in: The 2-5A System: Molecular and Clinical Aspects of the Interferon-Regulated Pathway, B. R. G. Williams and R. H. Silverman (eds.), Alan R. Liss Inc., New York, London (1985), pp. 25–34.
3. M. I. Jonston, W. G. Hearl, J. C. White, et al., “Immunochemistry, physical chemistry and biology of 2′,5′-oligoadenylates,” in: The 2-5A System: Molecular and Clinical Aspects of the Interferon-Regulated Pathway, B. R. G. Williams and R. H. Silverman (eds.), Alan R. Liss Inc., New York, London (1985) pp. 37–45.
4. H. Sawai, K. Ishibashi, M. Itoh, and S. Watanabe, “Radioimmunoassay for 2-5A using a novel 125I-labeled 2-5A analog, and analysis of 2-5A and 2-5A synthetase activity in human plasma,” in: The 2-5A System: Molecular and Clinical Aspects of the Interferon-Regulated Pathway, B. R. G. Williams and R. H. Silverman (eds.), Alan R. Liss Inc., New York, London (1985), pp. 97–104.
5. A. V. Itkes, V. L. Tunitskaya, and E. S. Severin, “Mechanisms underlying regulation of biological activity of the cell with the involvement of 2′,5′-oligoadenylate,” Biokhimiya, 50, No. 4, 531–542 (1985).